These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34269297)

  • 1. EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
    Zhu CM; Lian XY; Zhang HY; Bai L; Yun WJ; Zhao RH; Li QS
    J Cancer Res Ther; 2021 Jul; 17(3):664-670. PubMed ID: 34269297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis.
    Xu C; Zhou Q; Wu YL
    J Hematol Oncol; 2012 Oct; 5():62. PubMed ID: 23050865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
    Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
    Yan H; Li Q; Wang W; Zhen H; Cao B
    Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
    Ma J; Pang X; Zhang S; Huang L; Sun L; Han C
    Sci Rep; 2024 Oct; 14(1):22901. PubMed ID: 39358420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
    Lee CK; Brown C; Gralla RJ; Hirsh V; Thongprasert S; Tsai CM; Tan EH; Ho JC; Chu da T; Zaatar A; Osorio Sanchez JA; Vu VV; Au JS; Inoue A; Lee SM; Gebski V; Yang JC
    J Natl Cancer Inst; 2013 May; 105(9):595-605. PubMed ID: 23594426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
    Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients: Pooled analysis and subgroup analysis of efficacy and safety.
    Xu R; Shao H; Zhu J; Ju Q; Shi H
    Medicine (Baltimore); 2019 Mar; 98(13):e14135. PubMed ID: 30921175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
    Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
    PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis.
    Piotrowska Z; Yeap BY; Gainor JF
    ESMO Open; 2024 Sep; 9(9):103660. PubMed ID: 39168027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
    Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
    Cheng H; Li XJ; Wang XJ; Chen ZW; Wang RQ; Zhong HC; Wu TC; Cao QD
    Lung Cancer; 2019 Nov; 137():7-13. PubMed ID: 31520922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.